ArticleJournal of thrombosis and thrombolysis2022

Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States.

Jeffrey S Berger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.